Heartware International (HTWR) 10-Q 5 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 25, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'htwr	'
Entity Registrant Name	'HeartWare International, Inc.	'
Entity Central Index Key	'0001389072	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	17,003,784

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$146,595	$162,880
Short-term investments	36,104	37,596
Accounts receivable, net	36,487	28,052
Inventories	45,692	40,876
Prepaid expenses and other current assets	7,780	11,205
Total current assets	272,658	280,609
Property, plant and equipment, net	19,843	18,562
Goodwill	61,581	61,596
In-process research and development	35,500	35,500
Other intangible assets, net	16,010	15,975
Deferred financing costs, net	1,764	1,964
Long-term investments and other assets	14,855	15,621
Total assets	422,211	429,827
Current liabilities:	'	'
Accounts payable	11,794	17,914
Other accrued liabilities	35,348	35,276
Total current liabilities	47,142	53,190
Convertible senior notes, net	110,849	107,125
Contingent liabilities - See Note 4	56,440	67,000
Other long-term liabilities	3,991	3,905
Commitments and contingencies - See Note 12	'	'
Stockholders' equity:	'	'
Preferred stock - $.001 par value; 5,000 shares authorized; no shares issued and outstanding at June 30, 2014 and December 31, 2013	0	0
Common stock - $.001 par value; 25,000 shares authorized; 16,997 and 16,878 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	17	17
Additional paid-in capital	552,673	535,817
Accumulated deficit	-340,433	-329,353
Accumulated other comprehensive loss:	'	'
Cumulative translation adjustments	-8,427	-7,859
Unrealized loss on investments	-41	-15
Total accumulated other comprehensive loss	-8,468	-7,874
Total stockholders' equity	203,789	198,607
Total liabilities and stockholders' equity	$422,211	$429,827

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	25,000	25,000
Common stock, shares issued	16,997	16,878
Common stock, shares outstanding	16,997	16,878

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue, net	$70,131	$50,836	$136,603	$100,075
Cost of revenue	22,955	18,866	45,870	37,646
Gross profit	47,176	31,970	90,733	62,429
Operating expenses:	'	'	'	'
Selling, general and administrative	20,948	17,217	45,180	33,704
Research and development	26,913	24,188	59,504	46,330
Change in fair value of contingent consideration	-13,700	'	-10,560	'
Total operating expenses	34,161	41,405	94,124	80,034
Income (loss) from operations	13,015	-9,435	-3,391	-17,605
Other income (expense):	'	'	'	'
Foreign exchange gain (loss)	18	-619	191	-2,498
Interest expense	-3,251	-3,030	-6,447	-6,005
Investment income, net	199	68	406	109
Other, net	-1,264	82	-1,264	106
Income (loss) before income taxes	8,717	-12,934	-10,505	-25,893
Provision for income taxes	353	'	575	'
Net income (loss)	$8,364	($12,934)	($11,080)	($25,893)
Net income (loss) per common share:	'	'	'	'
Basic	$0.49	($0.79)	($0.65)	($1.66)
Diluted	$0.48	($0.79)	($0.65)	($1.66)
Weighted average shares outstanding:	'	'	'	'
Basic	16,989	16,370	16,962	15,619
Diluted	17,305	16,370	16,962	15,619

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Income Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]	'	'	'	'
Net income (loss)	$8,364	($12,934)	($11,080)	($25,893)
Other comprehensive income (loss)	'	'	'	'
Foreign currency translation adjustments	-328	390	-568	842
Unrealized loss on investments	-59	-12	-26	-44
Comprehensive income (loss)	$7,977	($12,556)	($11,674)	($25,095)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Common Shares [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
In Thousands, except Share data
Beginning balance at Dec. 31, 2013	$198,607	$17	$535,817	($329,353)	($7,874)
Beginning balance, Shares at Dec. 31, 2013	'	16,878,000	'	'	'
Issuance of common stock in connection with an intellectual property agreement	5,000	'	5,000	'	'
Issuance of common stock in connection with an intellectual property agreement, Shares	'	50,000	'	'	'
Issuance of common stock in connection with acquisition of CircuLite	329	'	329	'	'
Issuance of common stock in connection with acquisition of CircuLite, Shares	'	3,000	'	'	'
Issuance of common stock pursuant to share-based awards	613	'	613	'	'
Issuance of common stock pursuant to share-based awards, Shares	'	66,000	'	'	'
Share-based compensation	10,914	'	10,914	'	'
Net loss	-11,080	'	'	-11,080	'
Other comprehensive loss	-594	'	'	'	-594
Ending balance at Jun. 30, 2014	$203,789	$17	$552,673	($340,433)	($8,468)
Ending balance, Shares at Jun. 30, 2014	'	16,997,000	'	'	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2014
Common Shares, par value	$0.00
Common Shares [Member]	'
Common Shares, par value	$0.00

Condensed_Consolidated_Stateme4

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES	'	'
Net loss	($11,080)	($25,893)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of property, plant and equipment	3,208	3,204
Amortization of intangible assets	810	246
Impairment of fixed assets	607	0
Share-based compensation expense	10,914	9,377
Amortization of premium on investments	326	254
Amortization of discount on convertible senior notes	3,724	3,303
Amortization of deferred financing costs	200	176
Change in fair value of contingent consideration	-10,560	'
Other	1,305	95
Change in operating assets and liabilities:	'	'
Accounts receivable	-8,494	-8,665
Inventories	-5,559	410
Prepaid expenses and other current assets	2,912	-1,157
Accounts payable	-6,102	-1,165
Other accrued liabilities	5,416	-2,555
Other long-term liabilities	86	-40
Net cash used in operating activities	-12,287	-22,410
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Purchases of investments	-13,485	-17,965
Maturities of investments	14,625	1,981
Additions to property, plant and equipment, net	-4,453	-1,388
Additions to patents	-845	-410
Net cash used in investing activities	-4,158	-17,782
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from issuance of common stock	'	149,126
Payment of common stock issuance costs	'	-8,131
Proceeds from exercise of stock options	613	1,704
Net cash provided by financing activities	613	142,699
Effect of exchange rate changes on cash and cash equivalents	-453	1,596
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-16,285	104,103
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	162,880	85,921
CASH AND CASH EQUIVALENTS - END OF PERIOD	$146,595	$190,024

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Note 1. Basis of Presentation
	The accompanying unaudited interim condensed consolidated financial statements for HeartWare International, Inc. (“we,” “our,” “us,” “HeartWare,” the “HeartWare Group” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted. Accordingly, these statements do not include all the disclosures normally required by accounting principles generally accepted in the United States for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The accompanying condensed consolidated balance sheet as of December 31, 2013 has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2014 and cash flows for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for any future period or for the year ending December 31, 2014.
	The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
	In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). The updated standard is a new comprehensive revenue recognition model that requires revenue to be recognized in a manner that depicts the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is not permitted. The updated standard becomes effective for us in the first quarter of our fiscal year ending December 31, 2017. We have not yet selected a transition method and we are currently evaluating the effect that the ASU 2014-09 will have on our consolidated financial statements and related disclosures.
	With the exception of the standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2014, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, that are of significance or potential significance to us.

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Liquidity	'
	Note 2. Liquidity
	At June 30, 2014, we had approximately $183.9 million of cash, cash equivalents and investments.
	Our cash, cash equivalents and investments are expected to be used primarily to fund our ongoing operations including expanding our sales and marketing capabilities on a global basis, research and development (including clinical trials) of new and existing products, components and accessories, regulatory and other compliance functions as well as for general working capital. We believe our cash, cash equivalents and investment balances are sufficient to support our planned operations for at least the next twelve months.
	The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern. We have incurred substantial losses from operations since our inception through June 30, 2014, although for the quarter ended June 30, 2014 we recognized an operating profit as a result of a $13.7 million reduction in the fair value of contingent consideration (see Note 4). At June 30, 2014, we had an accumulated deficit of approximately $340.4 million.

Balance_Sheet_Information

Balance Sheet Information	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Balance Sheet Information	'
	Note 3. Balance Sheet Information
	Accounts Receivable
	Accounts receivable consists of amounts due from the sale of our HeartWare® Ventricular Assist System (the “HVAD System”) to our customers, which include hospitals, health research institutions and medical device distributors. We grant credit to customers in the normal course of business, but generally do not require collateral or any other security to support credit sales. Our receivables are geographically dispersed, with a significant portion from customers located in Europe and other foreign countries. One customer had an accounts receivable balance greater than 10% of total accounts receivable representing approximately 14% and 15% of our total accounts receivable at June 30, 2014 and December 31, 2013, respectively.
	We maintain allowances for doubtful accounts for estimated losses that may result from an inability to collect payments owed to us for product sales. We regularly review the allowance by considering factors such as historical experience, the age of the accounts receivable balances and local economic conditions that may affect a customer’s ability to pay. Account balances are charged off against the allowance after appropriate collection efforts have been exhausted and we feel it is probable that the receivable will not be recovered.
	The following table summarizes the change in our allowance for doubtful accounts for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	495			$	750
	Charges (reversals) to expense		—				—
	Charge-offs		—				—
	Ending balance	$	495			$	750
	As of June 30, 2014 and December 31, 2013, we did not have an allowance for returns.
	Inventories
	Components of inventories are as follows:
		June 30,				December 31,
		2014				2013
		(in thousands)
	Raw material	$	23,811			$	21,761
	Work-in-process		9,212				8,206
	Finished goods		12,669				10,909
		$	45,692			$	40,876
	Finished goods inventories includes inventory held on consignment at customer sites of approximately $5.1 million and $4.6 million at June 30, 2014 and December 31, 2013, respectively.
	Property, Plant and Equipment, Net
	Property, plant and equipment, net consists of the following:
		Estimated		June 30,				December 31,
		Useful Lives		2014				2013
				(in thousands)
	Machinery and equipment	1.5 to 7 years		$	20,862			$	19,790
	Leasehold improvements	3 to 10 years			8,564				7,131
	Office equipment, furniture and fixtures	5 to 7 years			1,901				1,294
	Purchased software	1 to 7 years			5,837				5,057
					37,164				33,272
	Less: accumulated depreciation				(17,321	)			(14,710	)
				$	19,843			$	18,562
	In the first quarter of 2014, we ceased activities at our facility in Teaneck, New Jersey and vacated the facility and recorded an impairment charge of $0.6 million related to certain office equipment and software at the facility upon their discontinued use. This amount is included in selling, general and administrative expenses on our condensed consolidated statements of operations.
	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
		June 30,				December 31,
		2014				2013
		(in thousands)
	Accrued payroll and other employee costs	$	9,012			$	10,840
	Accrued milestone payment		—				5,000
	Accrued material purchases		5,655				4,325
	Accrued warranty		3,400				2,498
	Accrued product recall costs		3,018				—
	Accrued professional fees		1,388				2,428
	Accrued research and development costs		2,656				2,307
	Accrued restructuring costs		2,026				245
	Accrued VAT		1,708				1,329
	Other accrued expenses		6,485				6,304
		$	35,348			$	35,276
	Accrued Payroll and Other Employee Costs
	Accrued payroll and other employee costs included estimated year-end employee bonuses of approximately $4.1 million and $6.6 million at June 30, 2014 and December 31, 2013, respectively.
	Accrued Warranty
	Certain patient accessories sold with the HVAD System are covered by a limited warranty ranging from one to two years. Estimated contractual warranty obligations are recorded as an expense when the related revenue is recognized and are included in cost of revenue on our condensed consolidated statements of operations. Factors that affect estimated warranty liability include the number of units sold, historical and anticipated rates of warranty claims, cost per claim, and vendor supported warranty programs. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The amount of the liability recorded is equal to the estimated costs to repair or otherwise satisfy claims made by customers.
	The following table summarizes changes in our warranty liability for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	2,498			$	543
	Accrual for warranty expense		1,790				500
	Warranty costs incurred during the period		(888	)			(345	)
	Ending balance	$	3,400			$	698
	The warranty liability as of June 30, 2014 takes into account recent substantial increases in product sales which are covered by our limited warranty policy.
Accrued Product Recall Costs
In April 2014, we implemented an Urgent Medical Device Correction following an observed increase in complaints related to earlier-than-expected battery depletion and routine battery handling. This notification provided information to assist patients and clinicians to monitor battery performance, recognize abnormal behaviors and reinforce proper power management of the HVAD System. We increased our warranty liability in the first quarter of 2014 to account for an anticipated higher level of battery returns likely to be associated with increased battery performance awareness following implementation of the field safety corrective action. On July 30, 2014, we extended our field safety corrective action to include a voluntary recall of certain older batteries. The recall instructs sites to replace certain older batteries in the field upon patients’ routine visits in order to further mitigate the potential risks associated with premature battery depletion.
The costs to repair or replace products associated with product recalls and voluntary service campaigns are recorded when they are determined to be probable and reasonably estimable as a cost of revenue and are not included in product warranty liability. During the quarter ended June 30, 2014, we recorded a $1.7 million charge for estimated costs associated with the battery recall discussed above.
Accrued Restructuring Costs
The following table summarizes changes in our accrued restructuring costs during the six months ended June 30, 2014:
	Facility Leases				Severance and				Contract			Total
					Related				Termination
	(in thousands)
Beginning balance	$	—			$	245			$	—		$	245
Restructuring charges		2,204				715				688			3,607
Payments		(449	)			(615	)			(688	)		(1,752	)
Adjustments to estimated obligations		(57	)			(31	)			—			(88	)
Change in fair value		14				—				—			14
Ending balance	$	1,712			$	314			$	—		$	2,026
The restructuring obligations reflected above resulted from the following actions:
Facility Closures
In the first quarter of 2014 we ceased the use of our facility in Teaneck, New Jersey, which was subject to an operating lease that runs through the end of 2020. In connection with this action, we recorded a $1.7 million liability equal to the estimated fair value of the remaining lease obligation as of the cease-use date (see Note 4). In the first quarter of 2014, we also relocated our corporate headquarters and ceased activities at our former headquarters in Framingham, Massachusetts. In connection with this action, we recorded a $0.5 million liability equal to the aggregate of the remaining payments on the lease for our former headquarters as of the cease-use date. Both of these items are included in selling, general and administrative expenses on our condensed consolidated statements of operations.
Severance Agreements
In the first six months of 2014, we incurred various costs related to the integration of CircuLite’s operations, including severance costs aggregating $0.6 million, the majority of which were recorded in the first quarter of 2014. We recorded $0.4 million in research and development expenses and the remaining $0.2 million in selling, general and administrative expenses on our condensed consolidated statements of operations.
Contract Termination
As a result of anticipated design modifications to the SYNERGY system and our decision to move manufacturing of the SYNERGY system to our Miami Lakes facility, we terminated a supply agreement with a vendor in Germany for the purchase of components necessary to produce the prior-to-modification version of the SYNERGY system. In connection with the termination of this supply agreement, we recorded a charge of $0.7 million in the first quarter of 2014, which is included in research and development expenses on our condensed consolidated statements of operations.

Fair_Value_Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Note 4. Fair Value Measurements
	FASB ASC 820 – Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to us as of the reporting dates. Accordingly, the estimates presented in the accompanying condensed consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments.
	FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).
	The three levels of the fair value hierarchy are as follows:
	Level 1 – Quoted prices for identical instruments in active markets.
	Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.
	Level 3 – Instruments with primarily unobservable value drivers.
	We review the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels of certain securities within the fair value hierarchy. There were no transfers between Level 1, Level 2 and Level 3 during the six months ended June 30, 2014 or 2013.
	The carrying amounts reported on our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term maturity of these instruments. Investments are considered available-for-sale as of June 30, 2014 and December 31, 2013 and are carried at fair value.
	The following tables represents the fair value of our financial assets and financial liabilities measured at fair value on a recurring basis and which level was used in the fair value hierarchy at the respective dates.
									Fair Value Measurements at the Reporting Date Using
			Carrying			Fair			Level 1		Level 2		Level 3
			Value			Value
			(in thousands)
	As of June 30, 2014
	Assets
	Short-term investments		$	36,104		$	36,104		$	—	$	36,104	$	—
	Long-term investments			1,225			1,225			—		1,225		—
	Liabilities
	Convertible senior notes			110,849	(1)		168,323			—		168,323		—
	Contingent consideration			56,440			56,440			—		—		56,440
	Royalties			965			965			—		—		965
	Lease exit costs			1,466			1,466			—		—		1,466
									Fair Value Measurements at the Reporting Date Using
			Carrying			Fair			Level 1		Level 2		Level 3
			Value			Value
			(in thousands)
	As of December 31, 2013
	Assets
	Short-term investments		$	37,596		$	37,596		$	—	$	37,596	$	—
	Long-term investments			1,225			1,225			—		1,225		—
	Liabilities
	Convertible senior notes			107,125	(1)		174,117			—		174,117		—
	Contingent consideration			67,000			67,000			—		—		67,000
	Royalties			999			999			—		—		999
	-1	The carrying amount of our convertible senior notes is net of unamortized discount. See Note 7 (Debt) for more information.
	Our Level 2 financial assets and liabilities include available-for-sale investments and convertible senior notes. The fair value of our available-for-sale investments and convertible senior notes was determined using quoted prices (including trade data) for the instruments in markets that are not active. The fair value of our convertible senior notes is presented for disclosure purposes only.
	Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques, and at least one significant model assumption or input is unobservable. Our Level 3 financial liabilities include the following:
		•		Contingent consideration – The estimated fair value of the contingent consideration related to our acquisition of CircuLite in December 2013 requires significant management judgment or estimation and is calculated using the income approach, using various revenue assumptions and applying a probability to each outcome. The fair value of the contingent consideration is remeasured at the estimated fair value at each reporting period. Actual amounts paid may differ from the obligations recorded.
		•		Royalties – Royalties represent future royalty payments to be made pursuant to agreements related to intellectual property licensed or acquired by World Heart Corporation, which we acquired in August 2012, to be paid over the next 3 to 17 years. Determination of fair value requires significant management judgment or estimation. The royalty payment obligations were valued using a discounted cash flow model, the future minimum royalty payment amounts and discount rates commensurate with our market risk and the terms of the obligations.
		•		Lease exit costs – In the first quarter of 2014 we ceased the use of our facility in Teaneck, New Jersey, which was subject to an operating lease that runs through the end of 2020, and we recorded a liability equal to the estimated fair value of the remaining lease payments as of the cease-use date. The fair value was estimated based upon the discounted present value of the remaining lease payments, considering future estimated sublease income, estimated broker fees and required tenant improvements. This estimated fair value requires significant management judgment. The fair value of this liability will be remeasured at estimated fair value at each reporting period. Actual amounts paid may differ from the obligation recorded.
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended June 30, 2014:
			Contingent
			Consideration
			(in thousands)
	Beginning balance		$	67,000
	Payments			—
	Change in fair value			(10,560	)
	Ending balance		$	56,440
	The change in fair value of the contingent consideration in the six months ended June 30, 2014 was primarily due to a $16.6 million reduction as a result of the probable unlikelihood of achieving the performance milestone conditions related to the re-launch of the SYNERGY Surgical System, which is undergoing redesign following its removal from the market in 2013 and loss of CE marking in the European Union in March 2014. This decrease in fair value was partially offset by a $6.0 million increase in fair value due to the effect of the passage of time on the fair value measurement. Adjustments associated with the change in fair value of contingent consideration are presented on a separate line item on our condensed consolidated statements of operations. Adjustments will be similarly presented in future accounting periods.
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the royalties for the six months ended June 30, 2014:
			Royalties
			(in thousands)
	Beginning balance		$	999
	Payments			(70	)
	Change in fair value			36
	Ending balance		$	965
	The expense associated with the change in fair value of the royalty payment obligations is included in research and development expenses on our condensed consolidated statements of operations.
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the lease exit costs for the six months ended June 30, 2014:
			Lease Exit
			Costs
			(in thousands)
	Beginning balance		$	—
Accruals			1,676
Payments			(224	)
Change in fair value			14
Ending balance		$	1,466
The expense associated with the change in fair value of the lease exit costs is included in selling, general and administrative expenses on our condensed consolidated statements of operations.
The following table presents quantitative information about the inputs and valuation methodologies used for our fair value measurements classified in Level 3 of the fair value hierarchy as of June 30, 2014:
		Fair Value at			Valuation Methodology		Significant	Weighted Average
		June 30, 2014					Unobservable Input	(range, if applicable)
		(in thousands)
Contingent consideration		$	56,440		Probability weighted income approach		Milestone dates		2019 to 2022
							Discount rate		20.0% to 24.0%
							Probability of occurrence		0% to 100%
Royalties		$	965		Discounted cash flow		Discount rate		4.8% to 7.8%
Lease exit costs		$	1,466		Discounted cash flow		Sublease start date		November 2015
							Sublease rate	$	26.50/square foot
							Discount rate		3.50%
Contingent Consideration
The estimated fair value of the contingent consideration related to the acquisition of CircuLite is calculated using the income approach, with significant inputs that include various revenue assumptions, discount rates and applying a probability to each outcome. Material changes in any of these inputs could result in a significantly higher or lower fair value measurement.
The estimated fair value of the contingent consideration is calculated on a quarterly basis by management. Potential valuation adjustments will be made as additional information becomes available, including, among other items, the progress toward achieving re-launch of the SYNERGY Surgical System, revenue and milestone targets as compared to initial projections, with the impact of these adjustments being recorded in our condensed consolidated statement of operations. In the three months ended June 30, 2014, we recorded a remeasurement adjustment to decrease the recorded value of the contingent consideration by $13.7 million. For the six months ended June 30, 2014, remeasurement adjustments decreased the recorded value of the contingent consideration by $10.6 million.
Assets That Are Measured at Fair Value on a Nonrecurring Basis
Non-financial assets such as intangible assets, goodwill and property, plant, and equipment are evaluated for impairment annually or when indicators of impairment exist. In the first quarter of 2014, we recorded an impairment charge of $0.6 million related to certain office equipment and software. No impairment was recorded in the three and six months ended June 30, 2013. Non-financial assets such as identified intangibles acquired in connection with our acquisition of World Heart in August 2012 and CircuLite in December 2013 are measured at fair value using Level 3 inputs, which include discounted cash flow methodologies, or similar techniques, when there is limited market activity and the determination of fair value requires significant judgment or estimation.

Investments

Investments	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Investments	'
	Note 5. Investments
	We have cash investment policies that limit investments to investment grade rated securities. At June 30, 2014 and December 31, 2013, all of our investments were classified as available-for-sale and carried at fair value. At June 30, 2014 and December 31, 2013, our short-term investments had maturity dates of less than twenty-four months and our long-term investments had maturity dates within thirty-six months.
	The amortized cost and fair value of our investments, with gross unrealized gains and losses, were as follows:
		Amortized		Gross		Gross			Aggregate
		Cost Basis		Unrealized		Unrealized			Fair Value
				Gains		Losses
	At June 30, 2014	(in thousands)
	Short-term investments:
	Corporate debt	$	29,286	$	17	$	(59	)	$	29,244
	Certificates of deposit		6,860		—		—			6,860
	Total short-term investments	$	36,146	$	17	$	(59	)	$	36,104
	Long-term investments:
	Certificates of deposit	$	1,225	$	—	$	—		$	1,225
	Total long-term investments	$	1,225	$	—	$	—		$	1,225
		Amortized		Gross		Gross			Aggregate
		Cost Basis		Unrealized		Unrealized			Fair Value
				Gains		Losses
	At December 31, 2013	(in thousands)
	Short-term investments:
	Corporate debt	$	32,221	$	3	$	(18	)	$	32,206
	Certificates of deposit		5,390		—		—			5,390
	Total short-term investments	$	37,611	$	3	$	(18	)	$	37,596
	Long-term investments:
	Certificates of deposit	$	1,225	$	—	$	—		$	1,225
	Total long-term investments	$	1,225	$	—	$	—		$	1,225
	For the three and six months ended June 30, 2014 and 2013, we did not have any realized gains or losses on our investments. At June 30, 2014 and December 31, 2013, none of our available-for-sale investments had been in a continuous loss position for more than twelve months.

Goodwill_InProcess_Research_an

Goodwill, In-Process Research and Development and Other Intangible Assets, Net	6 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Goodwill, In-Process Research and Development and Other Intangible Assets, Net	'
	Note 6. Goodwill, In-Process Research and Development and Other Intangible Assets, Net
	Goodwill
	The carrying amount of goodwill and the change in the balance for the six months ended June 30, 2014 and 2013 is as follows:
		2014			2013
		(in thousands)
	Beginning balance	$	61,596		$	1,190
	Additions		—			—
	Impairment		—			—
	Foreign currency translation impact		(15	)		—
	Ending balance	$	61,581		$	1,190
	In-Process Research and Development
	The carrying value of our in-process research and development assets, which relate to the development and potential commercialization of certain acquired technologies, consisted of the following at June 30, 2014 and December 31, 2013:
		June 30,			December 31,
		2014			2013
		(in thousands)
	SYNERGY system technology	$	35,500		$	35,500
	In-process research and development has an indefinite life. At the time the economic life becomes determinable (upon project completion or abandonment) the amount will be amortized over its expected remaining life.
	Other Intangible Assets
	Other intangible assets, net consisted of the following:
		June 30,			December 31,
		2014			2013
		(in thousands)
	Patents	$	4,599		$	3,754
	Purchased intangible assets
	Tradenames		3,700			3,700
	Customer relationships		1,800			1,800
	Acquired technology rights		7,925			7,925
			18,024			17,179
	Less: Accumulated amortization – Patents		(947	)		(800	)
	Less: Accumulated amortization – Purchased intangible assets		(1,067	)		(404	)
		$	16,010		$	15,975
	Our other intangible assets are amortized using the straight-line method over their estimated useful lives as follows:
	Patents		15 years
	Purchased intangible assets
	Tradenames		15 years
	Customer relationships		20 years
	Acquired technology rights		7 to 16 years
	Amortization expense for the three months ended June 30, 2014 and 2013 was $0.4 million and $0.1 million, respectively. Amortization expense for the six months ended June 30, 2014 and 2013 was $0.8 million and $0.2 million, respectively.

Debt

Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 7. Debt
	On December 15, 2010, we completed the sale of 3.5% convertible senior notes due 2017 (the “Convertible Notes”) for an aggregate principal amount of $143.75 million pursuant to the terms of an Indenture dated December 15, 2010 (the “Indenture”). The Convertible Notes are the senior unsecured obligations of the Company. The Convertible Notes bear interest at a rate of 3.5% per annum, payable semi-annually in arrears on June 15 and December 15 of each year. The Convertible Notes will mature on December 15, 2017, unless earlier repurchased by us or converted.
	The Convertible Notes offering was completed pursuant to a prospectus supplement, dated December 9, 2010, to a shelf registration statement on Form S-3 that was previously filed with the SEC and which was declared effective on December 9, 2010.
	The Convertible Notes will be convertible at an initial conversion rate of 10 shares of our common stock per $1,000 principal amount of Convertible Notes, which corresponds to an initial conversion price of $100.00 per share of our common stock. The conversion rate is subject to adjustment from time to time upon the occurrence of certain events.
	Prior to June 15, 2017, holders may convert their Convertible Notes at their option only upon satisfaction of one or more of the conditions specified in the Indenture relating to the (i) sale price of our common stock, (ii) the trading price per $1,000 principal amount of Convertible Notes or (iii) specified corporate events. As of the date of this report on Form 10-Q, none of the events that would allow holders to convert their Convertible Notes have occurred. On or after June 15, 2017, until the close of business of the business day immediately preceding the date the Convertible Notes mature, holders may convert their Convertible Notes at any time, regardless of whether any of the foregoing conditions have been met. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination thereof, at our election.
	We may not redeem the Convertible Notes prior to maturity. Holders of the Convertible Notes may require us to purchase for cash all or a part of their Convertible Notes at a repurchase price equal to 100% of the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes (as defined in the Indenture) involving the Company. The Indenture does not contain any financial or operating covenants or restrictions on the payments of dividends, the incurrence of indebtedness or the issuance or repurchase of securities by us or any of our subsidiaries.
	The Indenture contains customary terms and nonfinancial covenants and defines events of default. If an event of default (other than certain events of bankruptcy, insolvency or reorganization) involving the Company occurs and is continuing, the Trustee (by notice to the Company) or the holders of at least 25% in principal amount of the outstanding Convertible Notes (by notice to the Company and the Trustee) may declare 100% of the principal of and accrued and unpaid interest, if any, on all the Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company, 100% of the principal of and accrued and unpaid interest on the Convertible Notes will automatically become due and payable. Notwithstanding the foregoing, the Indenture provides that, to the extent we elect, the sole remedy for an event of default relating to certain failures by us to comply with certain reporting covenants in the Indenture consists exclusively of the right to receive additional interest on the Convertible Notes.
	In accordance with FASB ASC 470-20, Debt with Conversion and Other Options, which applies to certain convertible debt instruments that may be settled in cash or other assets, or partially in cash, upon conversion, we recorded the long-term debt and equity components on our Convertible Notes separately on the issuance date. The amount recorded for long-term debt was determined by measuring the fair value of a similar liability that does not have an associated equity component. The measurement of fair value required the Company to make estimates and assumptions to determine the present value of the cash flows of the Convertible Notes, absent the conversion feature. This treatment increased interest expense associated with our Convertible Notes by adding a non-cash component to interest expense in the form of amortization of a debt discount calculated based on the difference between the 3.5% cash coupon rate and the effective interest rate on debt borrowing of approximately 12.5%. The discount is being amortized to interest expense through the December 15, 2017 maturity date of the Convertible Notes using the effective interest method and is included in interest expense on our condensed consolidated statements of operations. Additionally, we allocated the costs related to issuance of the Convertible Notes on the same percentage as the long-term debt and equity components, such that a portion of the costs is allocated to the long-term debt component and the equity component included in additional paid-in capital. The portion of the costs allocated to the long-term debt component is presented as deferred financing costs, net on our condensed consolidated balance sheets. These deferred financing costs are also being amortized to interest expense through the December 15, 2017 maturity date of the Convertible Notes using the effective interest method and the amortization is included in interest expense on our condensed consolidated statements of operations.
	The Convertible Notes and the equity component, which is recorded in additional paid-in-capital, consisted of the following:
		June 30,			December 31,
		2014			2013
		(in thousands)
	Principal amount	$	143,750		$	143,750
	Unamortized discount		(32,901	)		(36,625	)
	Net carrying amount	$	110,849		$	107,125
	Equity component	$	55,038		$	55,038
	Based on the initial conversion rate of 10 shares of our common stock per $1,000 principal amount of Convertible Notes, which corresponds to an initial conversion price of $100.00 per share of our common stock, the number of shares issuable upon conversion of the Convertible Notes is 1,437,500. The value of these shares, based on the closing price of our common stock on June 30, 2014 of $88.50 per share, was approximately $127.2 million. The fair value of our Convertible Notes as presented in Note 4 was $168.3 million at June 30, 2014.
	Interest expense related to the Convertible Notes consisted of interest due on the principal amount, amortization of the discount and amortization of the portion of the deferred financing costs allocated to the long-term debt component. For the three and six months ended June 30, 2014 and 2013, interest expense related to the Convertible Notes was as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
		(in thousands)
	Stated amount at 3.5% coupon rate	$	1,258		$	1,258		$	2,516	$	2,516
	Amortization of discount		1,890			1,676			3,724		3,303
	Amortization of deferred financing costs		101			90			200		176
		$	3,249		$	3,024		$	6,440	$	5,995

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	Note 8. Stockholders’ Equity
	On March 12, 2013, we entered into an Underwriting Agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters named in the Underwriting Agreement (the “Underwriters”), pursuant to which we agreed to sell and the Underwriters agreed to purchase, subject to and upon terms and conditions set forth therein, an aggregate of 1,500,000 shares of our common stock at a net sales price of $81.9114 per share (the public offering price of $86.45 per share minus the underwriting discount). We also granted the Underwriters an option to purchase 225,000 additional shares of our common stock at the public offering price less the underwriting discount, which the Underwriters exercised in full on March 13, 2013. The closing of the offering occurred on March 18, 2013. After fees and related expenses, net proceeds from the offering were approximately $141.0 million.
	The offering was completed pursuant to a prospectus supplement, dated March 12, 2013, to a shelf registration statement on Form S-3 that was previously filed with the SEC and which was declared effective on December 9, 2010. This shelf registration statement expired on December 9, 2013.
	On January 30, 2014, we filed a shelf registration statement with the SEC on Form S-3. This shelf registration statement allows us to offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering any combination and amount of the securities described in the prospectus contained in the registration statement or in the prospectus supplement filed with respect to a particular offering. An aggregate of 530,816 shares of our common stock were registered for issuance pursuant to various prospectus filings on January 30, 2014 in connection with our acquisition of CircuLite. As of June 30, 2014, there remained 248,872 shares of our common stock reserved for potential issuance in connection with future contingent milestone payments under the terms of the acquisition agreement.
	Following satisfaction of a pre-specified milestone in December 2013, we were obligated to pay $5.0 million in cash or stock under the terms of a patent assignment agreement and exclusive license to certain patent applications. The $5.0 million was accrued at December 31, 2013 in other accrued liabilities on our consolidated balance sheets. We issued pursuant to a prospectus supplement an aggregate of 50,330 registered shares of our common stock in January 2014 to settle this liability.
	In the six months ended June 30, 2014, we issued an aggregate of 23,571 shares of our common stock upon the exercise of stock options and an aggregate of 42,088 shares of our common stock upon the vesting of restricted stock units.
	In the six months ended June 30, 2013, we issued an aggregate of 68,207 shares of our common stock upon the exercise of stock options and an aggregate of 21,661 shares of our common stock upon the vesting of restricted stock units.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	Note 9. Share-Based Compensation
	We allocate share-based compensation expense to cost of revenue, selling, general and administrative expense and research and development expense based on the award holder’s employment function. For the three and six months ended June 30, 2014 and 2013, we recorded share-based compensation expense as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
		(In thousands)
	Cost of revenues	$	662		$	611		$	1,109		$	1,142
	Selling, general and administrative		3,665			2,792			6,397			5,219
	Research and development		2,230			1,526			3,408			3,016
		$	6,557		$	4,929		$	10,914		$	9,377
	Equity Plans
	We have issued share-based awards to employees, non-executive directors and outside consultants through various approved plans and outside of any formal plan. New shares are issued upon the exercise of share-based awards.
	Upon receipt of stockholder approval on May 31, 2012, we adopted the HeartWare International, Inc. 2012 Incentive Award Plan (“2012 Plan”). The 2012 Plan provides for the grant of incentive stock options, non-qualified stock options, restricted stock, restricted stock units, performance awards, dividend equivalent rights, deferred stock, deferred stock units, stock payments and stock appreciation rights (collectively referred to as “Awards”), to our directors, employees and consultants. Under the terms of the 2012 Plan, the total number of shares of our common stock initially reserved for issuance under Awards is 1,375,000, provided that the total number of shares of our common stock that may be issued pursuant to “Full Value Awards” (Awards other than options, stock appreciation rights or other Awards for which the holder pays the intrinsic value existing as of the date of grant whether directly or by forgoing a right to receive a payment from the Company) is 1,275,000. As of June 30, 2014, 72,834 shares have been issued upon vesting of Awards issued under the 2012 Plan and Awards with respect to 561,322 shares were issued and outstanding under the 2012 Plan. Subsequent to adoption of the 2012 Plan, no new Awards will be granted under our prior plans. Any outstanding Awards under the prior plans will continue to be subject to the terms and conditions of the plan under which they were granted.
	Stock Options
	Each option allows the holder to subscribe for and be issued one share of our common stock at a specified price, which is generally the quoted market price of our common stock on the date the option is issued. Options generally vest on a pro-rata basis on each anniversary of the issuance date within four years of the date the option is issued. Options may be exercised after they have vested and prior to the specified expiry date provided applicable exercise conditions are met, if any. The expiry date can be for periods of up to ten years from the date the option is issued.
	The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model based on the assumptions established at that time. The following table includes the weighted average assumptions used for options issued in the three and six months ended June 30, 2014 and 2013.
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Dividend yield		0	%		0	%		0	%		0	%
	Expected volatility		39	%		40	%		39	%		40	%
	Risk-free interest rate		1.65	%		1.15	%		1.65	%		1.15	%
	Estimated holding period (years)		5			6.25			5			6.25
	Information related to options granted under all of our plans at June 30, 2014 and activity in the six months then ended is as follows (certain amounts in U.S.$ were converted from AU$ at the then period-end spot rate):
		Number of			Weighted			Weighted			Aggregate
		Options			Average			Average			Intrinsic
		(in thousands)			Exercise			Remaining			Value
					Price			Contractual Life			(in thousands)
								(Years)
	Outstanding at December 31, 2013		133		$	42.82
	Granted		7			88.84
	Exercised		(24	)		26.02
	Forfeited		(1	)		86.58
	Expired		—			—
	Outstanding at June 30, 2014		115		$	49.8			4.83		$	4,508
	Exercisable at June 30, 2014		94		$	41.88			3.97		$	4,382
	The aggregate intrinsic values at June 30, 2014 noted in the table above represent the number of in-the-money options outstanding or exercisable multiplied by the closing price of our common stock traded on NASDAQ less the weighted average exercise price at period end.
	The weighted average grant date fair value per share of options issued in the six months ended June 30, 2014 and 2013 was $32.41 and $38.51 per share, respectively.
	The total intrinsic value of options exercised in the six months ended June 30, 2014 and 2013 was approximately $1.6 million and $4.6 million, respectively. Cash received from options exercised in the six months ended June 30, 2014 and 2013 was approximately $0.6 million and $1.7 million, respectively.
	At June 30, 2014, there was approximately $0.4 million of unrecognized compensation expense, net of estimated forfeitures, related to non-vested options. This expense is expected to be recognized over a weighted average period of 1.1 years.
	Restricted Stock Units
	Each restricted stock unit (“RSU”) represents a contingent right to receive one share of our common stock. RSUs generally vest on a pro-rata basis on each anniversary of the issuance date over three or four years or vest in accordance with performance-based criteria. The RSUs with performance-based vesting criteria vest in one or more tranches contingent upon the achievement of pre-determined milestones related to the development of our products, the achievement of certain prescribed clinical and regulatory objectives, the achievement of specific financial performance measures or similar metrics. There is no consideration payable on the vesting of RSUs issued under the plans. Upon vesting, the RSUs are exercised automatically and settled in shares of our common stock.
	Information related to RSUs at June 30, 2014 and activity in the six months then ended is as follows:
		Number of			Weighted			Aggregate
		Units			Average			Intrinsic Value
		(in thousands)			Remaining			(in thousands)
					Contractual
					Life
					(Years)
	Outstanding at December 31, 2013		476
	Granted		315
	Vested/Exercised		(42	)
	Forfeited		(24	)
	Expired		—
	Outstanding at June 30, 2014		725			1.64		$	64,168
	The aggregate intrinsic value at June 30, 2014 noted in the table above represents the closing price of our common stock traded on NASDAQ multiplied by the number of RSUs outstanding.
	At June 30, 2014, 29,605 of the RSUs outstanding are subject to performance-based vesting criteria as described above.
	The total intrinsic value of RSUs vested in the six months ended June 30, 2014 and 2013 was approximately $4.0 million and $2.0 million, respectively.
	The fair value of each RSU award equals the closing price of our common stock on the date of grant. The weighted average grant date fair value per share of RSUs granted in the six months ended June 30, 2014 and 2013 was $100.57 and $92.07, respectively.
	At June 30, 2014, we had approximately $38.7 million of unrecognized compensation expense related to non-vested RSU awards, net of estimated forfeitures. This expense is expected to be recognized over a weighted average period of 1.6 years.

Earnings_Per_Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 10. Earnings Per Share
	Basic earnings per share was computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding for each respective period. Diluted earnings per share adjusts basic earnings per share for the dilutive effects of share-based awards as determined under the “treasury stock” method, our convertible senior notes as determined under the “if-converted” method and other potentially dilutive instruments only in the periods in which the effect is dilutive.
	The following table sets forth basic and diluted income (loss) per common share for the three and six months ended June 30, 2014 and 2013 (in thousands, except per share data):
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014			2013
	Numerator:
	Net income (loss)	$	8,364	$	(12,934	)	$	(11,080	)	$	(25,893	)
	Denominator:
	Basic weighted average shares outstanding		16,989		16,370			16,962			15,619
	Dilutive effects of share-based awards		316		—			—			—
	Diluted weighted-average shares outstanding		17,305		16,370			16,962			15,619
	Earnings (loss) per share:
	Basic	$	0.49	$	(0.79	)	$	(0.65	)	$	(1.66	)
	Diluted	$	0.48	$	(0.79	)	$	(0.65	)	$	(1.66	)
	The following instruments were excluded from the calculation of diluted weighted average shares outstanding, as their effect would be anti-dilutive.
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014			2013
	Common shares issuable upon:	(In thousands)
	Conversion of convertible senior notes		1,438		1,438			1,438			1,438
	Exercise or vesting of share-based awards		304		837			840			837

Business_Segment_Geographic_Ar

Business Segment, Geographic Areas and Major Customers	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Business Segment, Geographic Areas and Major Customers	'
	Note 11. Business Segment, Geographic Areas and Major Customers
	For financial reporting purposes, we have one reportable segment which designs, manufactures and markets medical devices for the treatment of advanced heart failure. Products are sold to customers located in the United States through our clinical trials and as commercial products, as commercial products to customers in Europe and under special access in other countries. Product sales attributed to a country or region are based on the location of the customer to whom the products are sold. Long-lived assets are primarily held in the United States.
	Product sales by geographic location were as follows:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)
	United States	$	36,945	$	25,106	$	70,733	$	51,256
	Germany		17,404		13,703		32,082		26,033
	International, excluding Germany		15,782		12,027		33,788		22,786
		$	70,131	$	50,836	$	136,603	$	100,075
	As a significant portion of our revenue is generated outside of the United States, we are dependent on favorable economic and regulatory environments for our products in Europe and other countries outside of the United States. For the three and six months ended June 30, 2014 and 2013, no customer exceeded 10% of product sales individually.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 12. Commitments and Contingencies
	We received a warning letter from the FDA, dated June 2, 2014, following an inspection of our Miami Lakes, Florida facility conducted in January 2014. The FDA letter cited four categories for us to address: (1) procedures for validating device design, including device labeling; (2) procedures for implementing corrective and preventive action (CAPA); (3) maintaining records related to investigations; and (4) validation of computer software used as part of production or quality systems. The warning letter did not require any action by physicians or patients and did not restrict use of HeartWare’s devices.
	We sent the FDA our initial response to the warning letter within the required fifteen business days of receipt, and committed to undertaking certain quality system improvements and providing the FDA with periodic updates. We have begun to implement systemic changes and organizational enhancements to address the four warning letter items and related quality systems. We have established teams to review and address the items cited by the FDA and have engaged external subject matter experts to assist in assessment and remediation efforts.
	At June 30, 2014, we had purchase order commitments of approximately $41.0 million related to product costs, supplies, services and property, plant and equipment purchases. Many of our materials and supplies require long lead times. Our purchase order commitments reflect materials that may be received up to one year from the date of order.
	In addition to the above, we have entered into employment agreements with all of our executive officers. These contracts do not have a fixed term and are constructed on an at-will basis. Some of these contracts provide executives with the right to receive certain additional payments and benefits if their employment is terminated including after a change of control, as defined in these agreements.
	From time to time we invest in certain development stage entities in connection with research activities. Certain contingent milestone payments in connection with these arrangements have not been accrued in the accompanying condensed consolidated financial statements as the amounts are indeterminate at this time.
	The taxation and customs requirements, together with other applicable laws and regulations of certain foreign jurisdictions, can be inherently complex and subject to differing interpretation by local authorities. We are subject to the risk that either we have misinterpreted applicable laws and regulations, or that foreign authorities may take inconsistent, unclear or changing positions on local law, customs practices or rules. In the event that we have misinterpreted any of the above, or that foreign authorities take positions contrary to ours, we may incur liabilities that may differ materially from the amounts accrued in the accompanying condensed consolidated financial statements.
	Contingent Consideration and Milestone Payments
	In December 2013, we acquired CircuLite using a combination of cash, stock and post-acquisition milestone payments. The milestone payments are payable based upon the achievement of six specified performance milestones over a 10 year period. The maximum amount of the aggregate milestone payments could be $320 million. As of June 30, 2014, the fair value of the contingent consideration was estimated to be $56.4 million (see Note 4).
	Litigation
	From time to time we may be involved in litigation or other contingencies arising in the ordinary course of business. Based on the information presently available, management believes there are no contingencies, claims or actions, pending or threatened, the ultimate resolution of which will have a material adverse effect on our financial position, liquidity or result of operations.
	In accordance with FASB ASC 450, Contingencies, we accrue loss contingencies including costs of settlement, damages and defense related to litigation to the extent they are probable and reasonably estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 13. Subsequent Events
	We have evaluated events and transactions that occurred subsequent to June 30, 2014 through the date the financial statements were issued, for potential recognition or disclosure in the accompanying condensed consolidated financial statements. Except as disclosed below, we did not identify any events or transactions that should be recognized or disclosed in the accompanying condensed consolidated financial statements.
	As described in Note 3, we extended our field safety corrective action on July 30, 2014 to include a voluntary recall of certain older batteries. The recall instructs sites to replace certain older batteries in the field upon patients’ routine visits in order to further mitigate the potential risks associated with premature battery depletion. We will continue to monitor complaints and may take further actions as appropriate.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Basis of Presentation	'
	The accompanying unaudited interim condensed consolidated financial statements for HeartWare International, Inc. (“we,” “our,” “us,” “HeartWare,” the “HeartWare Group” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted. Accordingly, these statements do not include all the disclosures normally required by accounting principles generally accepted in the United States for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. The accompanying condensed consolidated balance sheet as of December 31, 2013 has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations for the three and six months ended June 30, 2014 and cash flows for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for any future period or for the year ending December 31, 2014.
Accounting Estimates	'
	The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”). The updated standard is a new comprehensive revenue recognition model that requires revenue to be recognized in a manner that depicts the transfer of goods or services to a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. ASU 2014-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is not permitted. The updated standard becomes effective for us in the first quarter of our fiscal year ending December 31, 2017. We have not yet selected a transition method and we are currently evaluating the effect that the ASU 2014-09 will have on our consolidated financial statements and related disclosures.
	With the exception of the standard discussed above, there have been no other recent accounting pronouncements or changes in accounting pronouncements during the six months ended June 30, 2014, as compared to the recent accounting pronouncements described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, that are of significance or potential significance to us.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable consists of amounts due from the sale of our HeartWare® Ventricular Assist System (the “HVAD System”) to our customers, which include hospitals, health research institutions and medical device distributors. We grant credit to customers in the normal course of business, but generally do not require collateral or any other security to support credit sales. Our receivables are geographically dispersed, with a significant portion from customers located in Europe and other foreign countries. One customer had an accounts receivable balance greater than 10% of total accounts receivable representing approximately 14% and 15% of our total accounts receivable at June 30, 2014 and December 31, 2013, respectively.
	We maintain allowances for doubtful accounts for estimated losses that may result from an inability to collect payments owed to us for product sales. We regularly review the allowance by considering factors such as historical experience, the age of the accounts receivable balances and local economic conditions that may affect a customer’s ability to pay. Account balances are charged off against the allowance after appropriate collection efforts have been exhausted and we feel it is probable that the receivable will not be recovered.
	The following table summarizes the change in our allowance for doubtful accounts for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	495			$	750
	Charges (reversals) to expense		—				—
	Charge-offs		—				—
	Ending balance	$	495			$	750
	As of June 30, 2014 and December 31, 2013, we did not have an allowance for returns.
Property, Plant and Equipment, Net	'
	Property, plant and equipment, net consists of the following:
		Estimated		June 30,				December 31,
		Useful Lives		2014				2013
				(in thousands)
	Machinery and equipment	1.5 to 7 years		$	20,862			$	19,790
	Leasehold improvements	3 to 10 years			8,564				7,131
	Office equipment, furniture and fixtures	5 to 7 years			1,901				1,294
	Purchased software	1 to 7 years			5,837				5,057
					37,164				33,272
	Less: accumulated depreciation				(17,321	)			(14,710	)
				$	19,843			$	18,562
	In the first quarter of 2014, we ceased activities at our facility in Teaneck, New Jersey and vacated the facility and recorded an impairment charge of $0.6 million related to certain office equipment and software at the facility upon their discontinued use. This amount is included in selling, general and administrative expenses on our condensed consolidated statements of operations.
Accrued Warranty	'
	Accrued Warranty
	Certain patient accessories sold with the HVAD System are covered by a limited warranty ranging from one to two years. Estimated contractual warranty obligations are recorded as an expense when the related revenue is recognized and are included in cost of revenue on our condensed consolidated statements of operations. Factors that affect estimated warranty liability include the number of units sold, historical and anticipated rates of warranty claims, cost per claim, and vendor supported warranty programs. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. The amount of the liability recorded is equal to the estimated costs to repair or otherwise satisfy claims made by customers.
	The following table summarizes changes in our warranty liability for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	2,498			$	543
	Accrual for warranty expense		1,790				500
	Warranty costs incurred during the period		(888	)			(345	)
	Ending balance	$	3,400			$	698
	The warranty liability as of June 30, 2014 takes into account recent substantial increases in product sales which are covered by our limited warranty policy.
Fair Value Measurements	'
	The carrying amounts reported on our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term maturity of these instruments. Investments are considered available-for-sale as of June 30, 2014 and December 31, 2013 and are carried at fair value.
Debt	'
	In accordance with FASB ASC 470-20, Debt with Conversion and Other Options, which applies to certain convertible debt instruments that may be settled in cash or other assets, or partially in cash, upon conversion, we recorded the long-term debt and equity components on our Convertible Notes separately on the issuance date. The amount recorded for long-term debt was determined by measuring the fair value of a similar liability that does not have an associated equity component. The measurement of fair value required the Company to make estimates and assumptions to determine the present value of the cash flows of the Convertible Notes, absent the conversion feature. This treatment increased interest expense associated with our Convertible Notes by adding a non-cash component to interest expense in the form of amortization of a debt discount calculated based on the difference between the 3.5% cash coupon rate and the effective interest rate on debt borrowing of approximately 12.5%. The discount is being amortized to interest expense through the December 15, 2017 maturity date of the Convertible Notes using the effective interest method and is included in interest expense on our condensed consolidated statements of operations. Additionally, we allocated the costs related to issuance of the Convertible Notes on the same percentage as the long-term debt and equity components, such that a portion of the costs is allocated to the long-term debt component and the equity component included in additional paid-in capital. The portion of the costs allocated to the long-term debt component is presented as deferred financing costs, net on our condensed consolidated balance sheets. These deferred financing costs are also being amortized to interest expense through the December 15, 2017 maturity date of the Convertible Notes using the effective interest method and the amortization is included in interest expense on our condensed consolidated statements of operations.
Contingencies	'
	In accordance with FASB ASC 450, Contingencies, we accrue loss contingencies including costs of settlement, damages and defense related to litigation to the extent they are probable and reasonably estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Balance_Sheet_Information_Tabl

Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Summary of Change in Allowance for Doubtful Accounts	'
	The following table summarizes the change in our allowance for doubtful accounts for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	495			$	750
	Charges (reversals) to expense		—				—
	Charge-offs		—				—
	Ending balance	$	495			$	750
Components of Inventories	'
	Components of inventories are as follows:
		June 30,				December 31,
		2014				2013
		(in thousands)
	Raw material	$	23,811			$	21,761
	Work-in-process		9,212				8,206
	Finished goods		12,669				10,909
		$	45,692			$	40,876
Summary of Property, Plant and Equipment, Net	'
	Property, plant and equipment, net consists of the following:
		Estimated		June 30,				December 31,
		Useful Lives		2014				2013
				(in thousands)
	Machinery and equipment	1.5 to 7 years		$	20,862			$	19,790
	Leasehold improvements	3 to 10 years			8,564				7,131
	Office equipment, furniture and fixtures	5 to 7 years			1,901				1,294
	Purchased software	1 to 7 years			5,837				5,057
					37,164				33,272
	Less: accumulated depreciation				(17,321	)			(14,710	)
				$	19,843			$	18,562
Summary of Other Accrued Liabilities	'
	Other accrued liabilities consist of the following:
		June 30,				December 31,
		2014				2013
		(in thousands)
	Accrued payroll and other employee costs	$	9,012			$	10,840
	Accrued milestone payment		—				5,000
	Accrued material purchases		5,655				4,325
	Accrued warranty		3,400				2,498
	Accrued product recall costs		3,018				—
	Accrued professional fees		1,388				2,428
	Accrued research and development costs		2,656				2,307
	Accrued restructuring costs		2,026				245
	Accrued VAT		1,708				1,329
	Other accrued expenses		6,485				6,304
		$	35,348			$	35,276
Summary of Changes in Warranty Liability	'
	The following table summarizes changes in our warranty liability for the six months ended June 30, 2014 and 2013:
		2014				2013
		(in thousands)
	Beginning balance	$	2,498			$	543
	Accrual for warranty expense		1,790				500
	Warranty costs incurred during the period		(888	)			(345	)
	Ending balance	$	3,400			$	698
Summary of Changes in Accrued Restructuring Costs	'
	The following table summarizes changes in our accrued restructuring costs during the six months ended June 30, 2014:
		Facility Leases				Severance and				Contract			Total
						Related				Termination
		(in thousands)
	Beginning balance	$	—			$	245			$	—		$	245
	Restructuring charges		2,204				715				688			3,607
	Payments		(449	)			(615	)			(688	)		(1,752	)
	Adjustments to estimated obligations		(57	)			(31	)			—			(88	)
	Change in fair value		14				—				—			14
	Ending balance	$	1,712			$	314			$	—		$	2,026

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis	'
	The following tables represents the fair value of our financial assets and financial liabilities measured at fair value on a recurring basis and which level was used in the fair value hierarchy at the respective dates.
									Fair Value Measurements at the Reporting Date Using
			Carrying			Fair			Level 1		Level 2		Level 3
			Value			Value
			(in thousands)
	As of June 30, 2014
	Assets
	Short-term investments		$	36,104		$	36,104		$	—	$	36,104	$	—
	Long-term investments			1,225			1,225			—		1,225		—
	Liabilities
	Convertible senior notes			110,849	(1)		168,323			—		168,323		—
	Contingent consideration			56,440			56,440			—		—		56,440
	Royalties			965			965			—		—		965
	Lease exit costs			1,466			1,466			—		—		1,466
									Fair Value Measurements at the Reporting Date Using
			Carrying			Fair			Level 1		Level 2		Level 3
			Value			Value
			(in thousands)
	As of December 31, 2013
	Assets
	Short-term investments		$	37,596		$	37,596		$	—	$	37,596	$	—
	Long-term investments			1,225			1,225			—		1,225		—
	Liabilities
	Convertible senior notes			107,125	(1)		174,117			—		174,117		—
	Contingent consideration			67,000			67,000			—		—		67,000
	Royalties			999			999			—		—		999
	-1	The carrying amount of our convertible senior notes is net of unamortized discount. See Note 7 (Debt) for more information.
Summary of Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs	'
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the six months ended June 30, 2014:
			Contingent
			Consideration
			(in thousands)
	Beginning balance		$	67,000
	Payments			—
	Change in fair value			(10,560	)
	Ending balance		$	56,440
Summary of Change in Fair Value of Royalties as Determined by Level 3 Inputs	'
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the royalties for the six months ended June 30, 2014:
			Royalties
			(in thousands)
	Beginning balance		$	999
	Payments			(70	)
	Change in fair value			36
	Ending balance		$	965
Summary of Change in Fair Value of Lease Exit Costs as Determined by Level 3 Inputs	'
	The following table summarizes the change in fair value, as determined by Level 3 inputs, of the lease exit costs for the six months ended June 30, 2014:
			Lease Exit
			Costs
			(in thousands)
	Beginning balance		$	—
	Accruals			1,676
	Payments			(224	)
	Change in fair value			14
	Ending balance		$	1,466
Schedule of Quantitative Information for Level 3 Fair Value Measurements	'
	The following table presents quantitative information about the inputs and valuation methodologies used for our fair value measurements classified in Level 3 of the fair value hierarchy as of June 30, 2014:
			Fair Value at			Valuation Methodology		Significant	Weighted Average
			June 30, 2014					Unobservable Input	(range, if applicable)
			(in thousands)
	Contingent consideration		$	56,440		Probability weighted income approach		Milestone dates		2019 to 2022
								Discount rate		20.0% to 24.0%
								Probability of occurrence		0% to 100%
	Royalties		$	965		Discounted cash flow		Discount rate		4.8% to 7.8%
	Lease exit costs		$	1,466		Discounted cash flow		Sublease start date		November 2015
								Sublease rate	$	26.50/square foot
								Discount rate		3.50%

Investments_Tables

Investments (Tables)	6 Months Ended
	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Summary of Amortized Cost and Fair Value of Investments	'
	The amortized cost and fair value of our investments, with gross unrealized gains and losses, were as follows:
		Amortized		Gross		Gross			Aggregate
		Cost Basis		Unrealized		Unrealized			Fair Value
				Gains		Losses
	At June 30, 2014	(in thousands)
	Short-term investments:
	Corporate debt	$	29,286	$	17	$	(59	)	$	29,244
	Certificates of deposit		6,860		—		—			6,860
	Total short-term investments	$	36,146	$	17	$	(59	)	$	36,104
	Long-term investments:
	Certificates of deposit	$	1,225	$	—	$	—		$	1,225
	Total long-term investments	$	1,225	$	—	$	—		$	1,225
		Amortized		Gross		Gross			Aggregate
		Cost Basis		Unrealized		Unrealized			Fair Value
				Gains		Losses
	At December 31, 2013	(in thousands)
	Short-term investments:
	Corporate debt	$	32,221	$	3	$	(18	)	$	32,206
	Certificates of deposit		5,390		—		—			5,390
	Total short-term investments	$	37,611	$	3	$	(18	)	$	37,596
	Long-term investments:
	Certificates of deposit	$	1,225	$	—	$	—		$	1,225
	Total long-term investments	$	1,225	$	—	$	—		$	1,225

Goodwill_InProcess_Research_an1

Goodwill, In-Process Research and Development and Other Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill And Intangible Assets Disclosure [Abstract]	'
Summary of Carrying Amount of Goodwill and Change in Balance	'
	The carrying amount of goodwill and the change in the balance for the six months ended June 30, 2014 and 2013 is as follows:
		2014			2013
		(in thousands)
	Beginning balance	$	61,596		$	1,190
	Additions		—			—
	Impairment		—			—
	Foreign currency translation impact		(15	)		—
	Ending balance	$	61,581		$	1,190
Summary of Carrying Value of In-Process Research and Development Assets	'
	The carrying value of our in-process research and development assets, which relate to the development and potential commercialization of certain acquired technologies, consisted of the following at June 30, 2014 and December 31, 2013:
		June 30,			December 31,
		2014			2013
		(in thousands)
	SYNERGY system technology	$	35,500		$	35,500
Summary of Other Intangible Assets	'
	Other intangible assets, net consisted of the following:
		June 30,			December 31,
		2014			2013
		(in thousands)
	Patents	$	4,599		$	3,754
	Purchased intangible assets
	Tradenames		3,700			3,700
	Customer relationships		1,800			1,800
	Acquired technology rights		7,925			7,925
			18,024			17,179
	Less: Accumulated amortization – Patents		(947	)		(800	)
	Less: Accumulated amortization – Purchased intangible assets		(1,067	)		(404	)
		$	16,010		$	15,975
Estimated Useful Lives of Intangible Assets	'
	Our other intangible assets are amortized using the straight-line method over their estimated useful lives as follows:
	Patents		15 years
	Purchased intangible assets
	Tradenames		15 years
	Customer relationships		20 years
	Acquired technology rights		7 to 16 years

Debt_Tables

Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Summary of Convertible Notes and Equity Component	'
	The Convertible Notes and the equity component, which is recorded in additional paid-in-capital, consisted of the following:
		June 30,			December 31,
		2014			2013
		(in thousands)
	Principal amount	$	143,750		$	143,750
	Unamortized discount		(32,901	)		(36,625	)
	Net carrying amount	$	110,849		$	107,125
	Equity component	$	55,038		$	55,038
Summary of Interest Expense Related to Convertible Notes	'
	For the three and six months ended June 30, 2014 and 2013, interest expense related to the Convertible Notes was as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014		2013
		(in thousands)
	Stated amount at 3.5% coupon rate	$	1,258		$	1,258		$	2,516	$	2,516
	Amortization of discount		1,890			1,676			3,724		3,303
	Amortization of deferred financing costs		101			90			200		176
		$	3,249		$	3,024		$	6,440	$	5,995

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Allocation of Share-Based Compensation Expense	'
	For the three and six months ended June 30, 2014 and 2013, we recorded share-based compensation expense as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
		(In thousands)
	Cost of revenues	$	662		$	611		$	1,109		$	1,142
	Selling, general and administrative		3,665			2,792			6,397			5,219
	Research and development		2,230			1,526			3,408			3,016
		$	6,557		$	4,929		$	10,914		$	9,377
Weighted Average Assumptions Used for Options Issued	'
	The following table includes the weighted average assumptions used for options issued in the three and six months ended June 30, 2014 and 2013.
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Dividend yield		0	%		0	%		0	%		0	%
	Expected volatility		39	%		40	%		39	%		40	%
	Risk-free interest rate		1.65	%		1.15	%		1.65	%		1.15	%
	Estimated holding period (years)		5			6.25			5			6.25
Summary of Options Granted under All Plans	'
	Information related to options granted under all of our plans at June 30, 2014 and activity in the six months then ended is as follows (certain amounts in U.S.$ were converted from AU$ at the then period-end spot rate):
		Number of			Weighted			Weighted			Aggregate
		Options			Average			Average			Intrinsic
		(in thousands)			Exercise			Remaining			Value
					Price			Contractual Life			(in thousands)
								(Years)
	Outstanding at December 31, 2013		133		$	42.82
	Granted		7			88.84
	Exercised		(24	)		26.02
	Forfeited		(1	)		86.58
	Expired		—			—
	Outstanding at June 30, 2014		115		$	49.8			4.83		$	4,508
	Exercisable at June 30, 2014		94		$	41.88			3.97		$	4,382
Summary of RSU's	'
	Information related to RSUs at June 30, 2014 and activity in the six months then ended is as follows:
		Number of			Weighted			Aggregate
		Units			Average			Intrinsic Value
		(in thousands)			Remaining			(in thousands)
					Contractual
					Life
					(Years)
	Outstanding at December 31, 2013		476
	Granted		315
	Vested/Exercised		(42	)
	Forfeited		(24	)
	Expired		—

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Income (Loss) Per Common Share	'
	The following table sets forth basic and diluted income (loss) per common share for the three and six months ended June 30, 2014 and 2013 (in thousands, except per share data):
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014			2013
	Numerator:
	Net income (loss)	$	8,364	$	(12,934	)	$	(11,080	)	$	(25,893	)
	Denominator:
	Basic weighted average shares outstanding		16,989		16,370			16,962			15,619
	Dilutive effects of share-based awards		316		—			—			—
	Diluted weighted-average shares outstanding		17,305		16,370			16,962			15,619
	Earnings (loss) per share:
	Basic	$	0.49	$	(0.79	)	$	(0.65	)	$	(1.66	)
	Diluted	$	0.48	$	(0.79	)	$	(0.65	)	$	(1.66	)
Anti-Dilutive Securities Excluded from Computation of Weighted Average Shares Outstanding	'
	The following instruments were excluded from the calculation of diluted weighted average shares outstanding, as their effect would be anti-dilutive.
		Three Months Ended					Six Months Ended
		June 30,					June 30,
		2014		2013			2014			2013
	Common shares issuable upon:	(In thousands)
	Conversion of convertible senior notes		1,438		1,438			1,438			1,438
	Exercise or vesting of share-based awards		304		837			840			837

Business_Segment_Geographic_Ar1

Business Segment, Geographic Areas and Major Customers (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Product Sales by Geographic Location	'
	Product sales by geographic location were as follows:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
		(in thousands)
	United States	$	36,945	$	25,106	$	70,733	$	51,256
	Germany		17,404		13,703		32,082		26,033
	International, excluding Germany		15,782		12,027		33,788		22,786
		$	70,131	$	50,836	$	136,603	$	100,075

Liquidity_Additional_Informati

Liquidity - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013
Liquidity [Abstract]	'	'	'
Cash, cash equivalents and investments	$183,900,000	$183,900,000	'
Adjustments to contingent consideration	13,700,000	10,560,000	'
Accumulated deficit	($340,433,000)	($340,433,000)	($329,353,000)

Balance_Sheet_Information_Addi

Balance Sheet Information - Additional Information (Detail) (USD $)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
	Customer			Customer		Customer
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Percentage of account receivables by customers	10.00%	'	'	10.00%	'	10.00%
Number of customers having account receivable balance	1	'	'	1	'	1
Percentage of accounts receivable from major customer	14.00%	'	'	14.00%	'	15.00%
Allowance for returns	'	'	'	$0	'	$0
Inventory held on consignment	5,100,000	'	'	5,100,000	'	4,600,000
Impairment charge	'	600,000	0	607,000	0	'
Accrued payroll and other employee costs	4,100,000	'	'	4,100,000	'	6,600,000
Cost of revenue	22,955,000	'	18,866,000	45,870,000	37,646,000	'
Lease liability	'	1,700,000	'	'	'	'
Remaining lease payments	'	500,000	'	'	'	'
Lease expiration year	'	'	'	'2020	'	'
Research and development	26,913,000	'	24,188,000	59,504,000	46,330,000	'
Selling, general and administrative	20,948,000	'	17,217,000	45,180,000	33,704,000	'
CircuLite [Member]	'	'	'	'	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Aggregate severance costs	'	600,000	'	600,000	'	'
Research and development	'	'	'	400,000	'	'
Selling, general and administrative	'	'	'	200,000	'	'
Contract termination fee	'	700,000	'	'	'	'
Product Recall Expense [Member]	'	'	'	'	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Cost of revenue	'	'	'	1,700,000	'	'
Office Equipment and Software [Member]	'	'	'	'	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Impairment charge	'	$600,000	'	'	'	'
Minimum [Member]	'	'	'	'	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Maturity of limited warranty	'	'	'	'1 year	'	'
Maximum [Member]	'	'	'	'	'	'
Condensed Balance Sheet Statements, Captions [Line Items]	'	'	'	'	'	'
Maturity of limited warranty	'	'	'	'2 years	'	'

Balance_Sheet_Information_Summ

Balance Sheet Information - Summary of Change in Allowance for Doubtful Accounts (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Accounting Policies [Abstract]	'	'
Beginning balance	$495	$750
Charges (reversals) to expense	0	0
Charge-offs	0	0
Ending balance	$495	$750

Balance_Sheet_Information_Comp

Balance Sheet Information - Components of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw material	$23,811	$21,761
Work-in-process	9,212	8,206
Finished goods	12,669	10,909
Inventory, total	$45,692	$40,876

Balance_Sheet_Information_Summ1

Balance Sheet Information - Summary of Property, Plant and Equipment, Net (Detail) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

In Thousands, unless otherwise specified

Machinery and Equipment [Member]

Machinery and Equipment [Member]

Machinery and Equipment [Member]

Machinery and Equipment [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Leasehold Improvements [Member]

Office Equipment, Furniture and Fixtures [Member]

Office Equipment, Furniture and Fixtures [Member]

Office Equipment, Furniture and Fixtures [Member]

Office Equipment, Furniture and Fixtures [Member]

Purchased Software [Member]

Purchased Software [Member]

Purchased Software [Member]

Purchased Software [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Property, Plant and Equipment [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment, estimated useful lives

'

'

'

'

'1 year 6 months

'7 years

'

'

'3 years

'10 years

'

'

'5 years

'7 years

'

'

'1 year

'7 years

Property, plant and equipment, gross

$37,164

$33,272

$20,862

$19,790

'

'

$8,564

$7,131

'

'

$1,901

$1,294

'

'

$5,837

$5,057

'

'

Less: accumulated depreciation

-17,321

-14,710

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property, plant and equipment, net

$19,843

$18,562

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance_Sheet_Information_Summ2

Balance Sheet Information - Summary of Other Accrued Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables And Accruals [Abstract]	'	'	'	'
Accrued payroll and other employee costs	$9,012	$10,840	'	'
Accrued milestone payment	'	5,000	'	'
Accrued material purchases	5,655	4,325	'	'
Accrued warranty	3,400	2,498	698	543
Accrued product recall costs	3,018	'	'	'
Accrued professional fees	1,388	2,428	'	'
Accrued research and development costs	2,656	2,307	'	'
Accrued restructuring costs	2,026	245	'	'
Accrued VAT	1,708	1,329	'	'
Other accrued expenses	6,485	6,304	'	'
Total other accrued liabilities	$35,348	$35,276	'	'

Balance_Sheet_Information_Summ3

Balance Sheet Information - Summary of Changes in Warranty Liability (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Accounting Policies [Abstract]	'	'
Beginning balance	$2,498	$543
Accrual for warranty expense	1,790	500
Warranty costs incurred during the period	-888	-345
Ending balance	$3,400	$698

Balance_Sheet_Information_Summ4

Balance Sheet Information - Summary of Changes in Accrued Restructuring Costs (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Restructuring Cost and Reserve [Line Items]	'
Beginning balance	$245
Restructuring charges	3,607
Payments	-1,752
Adjustments to estimated obligations	-88
Change in fair value	14
Ending balance	2,026
Facility Leases [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Beginning balance	0
Restructuring charges	2,204
Payments	-449
Adjustments to estimated obligations	-57
Change in fair value	14
Ending balance	1,712
Severance and Related [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Beginning balance	245
Restructuring charges	715
Payments	-615
Adjustments to estimated obligations	-31
Change in fair value	0
Ending balance	314
Contract Termination [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Beginning balance	0
Restructuring charges	688
Payments	-688
Change in fair value	0
Ending balance	$0

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'
Transfer between level 1, Level 2, Level3	'	'	'	$0	$0
Change in fair value of contingent consideration	6,000,000	'	'	6,000,000	'
Adjustments to contingent consideration	13,700,000	'	'	10,560,000	'
Impairment charge	'	600,000	0	607,000	0
Performance Milestone Goal [Member]	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'
Change in fair value of contingent consideration	$16,600,000	'	'	$16,600,000	'
Minimum [Member] | World Heart Corporation [Member]	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'
Period for royalty payment obligations	'	'	'	'3 years	'
Maximum [Member] | World Heart Corporation [Member]	'	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'	'
Period for royalty payment obligations	'	'	'	'17 years	'

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	$36,104	$37,596
Convertible senior notes	110,849	107,125
Contingent consideration	56,440	67,000
Level 1 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	0	0
Long-term investments	0	0
Convertible senior notes	0	0
Contingent consideration	0	0
Royalties	0	0
Lease exit costs	0	'
Level 2 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	36,104	37,596
Long-term investments	1,225	1,225
Convertible senior notes	168,323	174,117
Contingent consideration	0	0
Royalties	0	0
Lease exit costs	0	'
Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	0	0
Long-term investments	0	0
Convertible senior notes	0	0
Contingent consideration	56,440	67,000
Royalties	965	999
Lease exit costs	1,466	'
Carrying Value [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	36,104	37,596
Long-term investments	1,225	1,225
Convertible senior notes	110,849	107,125
Contingent consideration	56,440	67,000
Royalties	965	999
Lease exit costs	1,466	'
Fair Value [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Short-term investments	36,104	37,596
Long-term investments	1,225	1,225
Convertible senior notes	168,323	174,117
Contingent consideration	56,440	67,000
Royalties	965	999
Lease exit costs	1,466	'
Fair Value [Member] | Level 3 [Member]	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'
Contingent consideration	56,440	'
Royalties	965	'
Lease exit costs	$1,466	'

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs (Detail) (USD $)	3 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	'	$67,000
Change in fair value	-13,700	-10,560
Ending balance	56,440	56,440
Level 3 [Member]	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	'	67,000
Payments	'	'
Change in fair value	'	-10,560
Ending balance	$56,440	$56,440

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Change in Fair Value of Royalties as Determined by Level 3 Inputs (Detail) (Level 3 [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Level 3 [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning balance	$999
Payments	-70
Change in fair value	36
Ending balance	$965

Fair_Value_Measurements_Summar2

Fair Value Measurements - Summary of Change in Fair Value of Lease Exit Costs as Determined by Level 3 Inputs (Detail) (Level 3 [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014
Level 3 [Member]	'
Fair Value Assets Measured On Recurring and Nonrecurring Basis [Line Items]	'
Beginning balance	$0
Accruals	1,676
Payments	-224
Change in fair value	14
Ending balance	$1,466

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Quantitative Information for Level 3 Fair Value Measurements (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Contingent consideration	$56,440	$67,000
Fair Value [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Contingent consideration	56,440	67,000
Royalties	965	999
Lease exit costs	1,466	'
Level 3 [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Contingent consideration	56,440	67,000
Royalties	965	999
Sublease rate	26.5	'
Lease exit costs	1,466	'
Discount rate	3.50%	'
Level 3 [Member] | Fair Value [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Contingent consideration	56,440	'
Royalties	965	'
Lease exit costs	$1,466	'
Level 3 [Member] | Contingent Consideration [Member] | Minimum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Discount rate	20.00%	'
Probability of occurrence	0.00%	'
Level 3 [Member] | Contingent Consideration [Member] | Minimum [Member] | Probability Weighted Income Approach [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Milestone dates	'2019	'
Level 3 [Member] | Contingent Consideration [Member] | Maximum [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Discount rate	24.00%	'
Probability of occurrence	100.00%	'
Level 3 [Member] | Contingent Consideration [Member] | Maximum [Member] | Probability Weighted Income Approach [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Milestone dates	'2022	'
Level 3 [Member] | Royalties [Member] | Minimum [Member] | Discounted Cash Flow [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Discount rate	4.80%	'
Level 3 [Member] | Royalties [Member] | Maximum [Member] | Discounted Cash Flow [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Discount rate	7.80%	'
Level 3 [Member] | Lease Exit Costs [Member] | Discounted Cash Flow [Member]	'	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'	'
Sublease start date	'November 2015	'

Investments_Additional_Informa

Investments - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended			6 Months Ended	12 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Dec. 31, 2013
						Short-Term Investments [Member]	Short-Term Investments [Member]	Long-Term Investments [Member]	Long-Term Investments [Member]
Schedule of Available-for-sale Securities [Line Items]	'	'	'	'	'	'	'	'	'
Investment maturity date description	'	'	'	'	'	'Less than twenty-four months	'Less than twenty-four months	'Within thirty-six months	'Within thirty-six months
Realized gains (losses) on investments	$0	$0	$0	$0	'	'	'	'	'
Available-for-sale investments in a continuous loss position for more than twelve months	$0	'	$0	'	$0	'	'	'	'

Investments_Summary_of_Amortiz

Investments - Summary of Amortized Cost and Fair Value of Investments (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Short-Term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost Basis	$36,146	$37,611
Gross Unrealized Gains	17	3
Gross Unrealized Losses	-59	-18
Aggregate Fair Value	36,104	37,596
Short-Term Investments [Member] | Corporate Debt [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost Basis	29,286	32,221
Gross Unrealized Gains	17	3
Gross Unrealized Losses	-59	-18
Aggregate Fair Value	29,244	32,206
Short-Term Investments [Member] | Certificates of Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost Basis	6,860	5,390
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	6,860	5,390
Long-Term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost Basis	1,225	1,225
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	1,225	1,225
Long-Term Investments [Member] | Certificates of Deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost Basis	1,225	1,225
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$1,225	$1,225

Goodwill_InProcess_Research_an2

Goodwill, In-Process Research and Development and Other Intangible Assets, Net - Summary of Carrying Amount of Goodwill and Change in Balance (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Intangible Liability Disclosure [Abstract]	'	'
Beginning balance	$61,596	$1,190
Additions	'	'
Impairment	'	'
Foreign currency translation impact	-15	'
Ending balance	$61,581	$1,190

Goodwill_InProcess_Research_an3

Goodwill, In-Process Research and Development and Other Intangible Assets, Net - Summary of Carrying Value of In-Process Research and Development Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible Liability Disclosure [Abstract]	'	'
Carrying value of in-process research and development assets	$35,500	$35,500

Goodwill_InProcess_Research_an4

Goodwill, In-Process Research and Development and Other Intangible Assets, Net - Summary of Other Intangible Assets (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets	$18,024	$17,179
Other intangible assets, net	16,010	15,975
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets	4,599	3,754
Less: Accumulated amortization	-947	-800
Tradenames [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets	3,700	3,700
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets	1,800	1,800
Acquired Technology Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Other intangible assets	7,925	7,925
Purchased Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Less: Accumulated amortization	($1,067)	($404)

Goodwill_InProcess_Research_an5

Goodwill, In-Process Research and Development and Other Intangible Assets, Net - Estimated Useful Lives of Intangible Assets (Detail)	6 Months Ended
	Jun. 30, 2014
Patents [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives	'15 years
Tradenames [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives	'15 years
Customer Relationships [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives	'20 years
Minimum [Member] | Acquired Technology Rights [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives	'7 years
Maximum [Member] | Acquired Technology Rights [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
Estimated useful lives	'16 years

Goodwill_InProcess_Research_an6

Goodwill, In-Process Research and Development and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Goodwill And Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization expense	$400	$100	$810	$246

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 15, 2010
Debt Instrument [Line Items]	'	'	'	'
Maturity of convertible and promissory notes	15-Dec-17	'	'	'
Interest of convertible notes	3.50%	'	'	3.50%
Aggregate principal amount of convertible senior notes	$143,750,000	$143,750,000	'	$143,750,000
Payable semi-annually in arrear	'June 15 and December 15	'	'	'
Conversion of shares	10	'	'	'
Principal amount of Convertible Notes	1,000	'	'	'
Initial conversion price	$100	'	'	'
Principal amount of the Convertible Notes part of repurchase price	100.00%	'	'	'
Principal amount of Convertible Notes part of owners	25.00%	'	'	'
Coupon rate	3.50%	'	3.50%	'
Effective interest rate on debt borrowing	12.50%	'	'	'
Number of shares issuable upon conversion of the Convertible Notes	1,437,500	'	'	'
Convertible value of instrument for convertible debt	127,200,000	'	'	'
Fair value of Convertible Notes	$168,300,000	'	'	'
Common Shares [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Closing price	$88.50	'	'	'

Debt_Summary_of_Convertible_No

Debt - Summary of Convertible Notes and Equity Component (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 15, 2010
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'	'
Principal amount	$143,750	$143,750	$143,750
Unamortized discount	-32,901	-36,625	'
Net carrying amount	110,849	107,125	'
Equity component	$55,038	$55,038	'

Debt_Summary_of_Interest_Expen

Debt - Summary of Interest Expense Related to Convertible Notes (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Debt Disclosure [Abstract]	'	'	'	'
Stated amount at 3.5% coupon rate	$1,258	$1,258	$2,516	$2,516
Amortization of discount	1,890	1,676	3,724	3,303
Amortization of deferred financing costs	101	90	200	176
Convertible Notes interest expense, Net	$3,249	$3,024	$6,440	$5,995

Debt_Summary_of_Interest_Expen1

Debt - Summary of Interest Expense Related to Convertible Notes (Parenthetical) (Detail)	Jun. 30, 2014	Jun. 30, 2013
Debt Disclosure [Abstract]	'	'
Coupon rate	3.50%	3.50%

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	0 Months Ended			1 Months Ended	6 Months Ended			1 Months Ended
	Mar. 18, 2013	Mar. 13, 2013	Mar. 12, 2013	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Jun. 30, 2014	Jan. 30, 2014
								Patents [Member]	CircuLite [Member]	CircuLite [Member]
Schedule Of Stockholders Equity [Line Items]	'	'	'	'	'	'	'	'	'	'
Shares offered under Underwriting Agreement	'	'	1,500,000	'	'	'	'	'	'	'
Net sales price, per share	'	'	$81.91	'	'	'	'	'	'	'
Offering price, per share	'	'	$86.45	'	'	'	'	'	'	'
Additional shares offered under Underwriting Agreement	'	225,000	'	'	'	'	'	'	'	'
Issuance of common stock pursuant to public offering, net of offering costs	$141,000,000	'	'	'	'	'	'	'	'	'
Shelf registration statement expiration date	'	'	'	'	9-Dec-13	'	'	'	'	'
Shares registered for issuance for acquisition	'	'	'	'	'	'	'	'	'	530,816
Shares reserved in connection with future contingent milestone payments	'	'	'	'	'	'	'	'	248,872	'
Additional acquired technology rights	'	'	'	'	'	'	'	5,000,000	'	'
Accrued milestone payment	'	'	'	'	'	'	$5,000,000	'	'	'
Common stock issued to settle liability	'	'	'	50,330	'	'	'	'	'	'
Common stock issued upon the exercise of stock options	'	'	'	'	23,571	68,207	'	'	'	'
Common stock upon the vesting of restricted stock units	'	'	'	'	42,088	21,661	'	'	'	'

ShareBased_Compensation_Alloca

Share-Based Compensation - Allocation of Share-Based Compensation Expense (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Recorded share-based compensation expense	$6,557	$4,929	$10,914	$9,377
Cost of Revenues [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Recorded share-based compensation expense	662	611	1,109	1,142
Selling, General and Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Recorded share-based compensation expense	3,665	2,792	6,397	5,219
Research and Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Recorded share-based compensation expense	$2,230	$1,526	$3,408	$3,016

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)

6 Months Ended

6 Months Ended

0 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

31-May-12

31-May-12

Jun. 30, 2014

Exercise or Vesting of Share-Based Awards [Member]

Exercise or Vesting of Share-Based Awards [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

Restricted Stock Units (RSUs) [Member]

2012 Plan Award [Member]

2012 Plan Award [Member]

Full Value Awards [Member]

Performance-Based Unit (PSUs) [Member]

Minimum [Member]

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance under 2012 incentive award plan

'

'

'

'

'

'

'

'

'

'

1,375,000

1,275,000

'

Share issued upon vesting of Awards

23,571

68,207

'

'

'

'

'

'

'

72,834

'

'

'

Stock options issued

7,000

'

'

'

'

'

'

'

'

561,322

'

'

'

Stock options outstanding

115,000

'

133,000

'

'

'

'

'

'

0

'

'

'

Performance based option vesting period

'

'

'

'4 years

'

'

'

'3 years

'4 years

'

'

'

'

Option expiry period

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant date fair value per share option

$32.41

$38.51

'

'

'

'

'

'

'

'

'

'

'

Aggregate Intrinsic value options

'

'

'

$1,600,000

$4,600,000

'

'

'

'

'

'

'

'

Cash received from options exercised

613,000

1,704,000

'

600,000

1,700,000

'

'

'

'

'

'

'

'

Unrecognized compensation expense related to non-vested option awards

'

'

'

400,000

'

38,700,000

'

'

'

'

'

'

'

Recognized over a weighted average period

'

'

'

'1 year 1 month 6 days

'

'1 year 7 months 6 days

'

'

'

'

'

'

'

Contingent right to receive share of common stock

'

'

'

'

'

1

'

'

'

'

'

'

'

RSU's outstanding

'

'

'

'

'

'

'

'

'

'

'

'

29,605

Restricted stock units vested intrinsic value

'

'

'

'

'

$4,000,000

$2,000,000

'

'

'

'

'

'

Weighted average grant date fair value per share other than option

'

'

'

'

'

$100.57

$92.07

'

'

'

'

'

'

ShareBased_Compensation_Weight

Share-Based Compensation - Weighted Average Assumptions Used for Options Issued (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected volatility	39.00%	40.00%	39.00%	40.00%
Risk-free interest rate	1.65%	1.15%	1.65%	1.15%
Estimated holding period (years)	'5 years	'6 years 3 months	'5 years	'6 years 3 months

ShareBased_Compensation_Summar

Share-Based Compensation - Summary of Options Granted under All Plans (Detail) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Number of Options	'	'
Outstanding, Beginning Balance	133,000	'
Granted	7,000	'
Exercised	-23,571	-68,207
Forfeited	-1,000	'
Outstanding, Ending Balance	115,000	'
Exercisable, Ending Balance	94,000	'
Weighted Average Exercise Price	'	'
Outstanding, Beginning Balance	$42.82	'
Granted	$88.84	'
Exercised	$26.02	'
Forfeited	$86.58	'
Outstanding, Ending Balance	$49.80	'
Exercisable, Ending Balance	$41.88	'
Weighted Average Remaining Contractual Life	'	'
Outstanding, Ending Balance	'4 years 9 months 29 days	'
Exercisable, Ending Balance	'3 years 11 months 19 days	'
Aggregate Intrinsic Value	'	'
Outstanding, Ending Balance	$4,508	'
Exercisable, Ending Balance	$4,382	'

ShareBased_Compensation_Summar1

Share-Based Compensation - Summary of RSU's (Detail) (USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Number of Restricted Stock Units	'	'
Vested/Exercised	-42,088	-21,661
Restricted Stock Units (RSUs) [Member]	'	'
Number of Restricted Stock Units	'	'
Outstanding, Beginning Balance	476,000	'
Granted	315,000	'
Vested/Exercised	-42,000	'
Forfeited	-24,000	'
Expired	0	'
Outstanding, Ending Balance	725,000	'
Weighted Average Remaining Contractual Life	'	'
Outstanding, Ending Balance	'1 year 7 months 21 days	'
Aggregate Intrinsic Value	'	'
Outstanding, Ending Balance	64,168	'

Earnings_Per_Share_Basic_and_D

Earnings Per Share - Basic and Diluted Income (Loss) Per Common Share (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Numerator:	'	'	'	'
Net income (loss)	$8,364	($12,934)	($11,080)	($25,893)
Denominator:	'	'	'	'
Basic weighted average shares outstanding	16,989	16,370	16,962	15,619
Dilutive effects of share-based awards	316	0	0	0
Diluted weighted-average shares outstanding	17,305	16,370	16,962	15,619
Earnings (loss) per share:	'	'	'	'
Basic	$0.49	($0.79)	($0.65)	($1.66)
Diluted	$0.48	($0.79)	($0.65)	($1.66)

Earnings_Per_Share_AntiDilutiv

Earnings Per Share - Anti-Dilutive Securities Excluded from Computation of Weighted Average Shares Outstanding (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Conversion of Convertible Senior Notes [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities excluded	1,438	1,438	1,438	1,438
Exercise or Vesting of Share-Based Awards [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities excluded	304	837	840	837

Business_Segment_Geographic_Ar2

Business Segment, Geographic Areas and Major Customers - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
	Customer	Customer	Customer	Customer
			Segment
Segment Reporting [Abstract]	'	'	'	'
Number of reportable segments	'	'	1	'
Number of customers exceeding ten percent of sales	0	0	0	0
Percentage of minimum product sales	10.00%	10.00%	10.00%	10.00%

Business_Segment_Geographic_Ar3

Business Segment, Geographic Areas and Major Customers - Product Sales by Geographic Location (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue, net	$70,131	$50,836	$136,603	$100,075
United States [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue, net	36,945	25,106	70,733	51,256
Germany [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue, net	17,404	13,703	32,082	26,033
International, Excluding Germany [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue, net	$15,782	$12,027	$33,788	$22,786

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
	Milestone
Commitments And Contingencies Disclosure [Abstract]	'	'
Purchase order commitments	'Approximately $41.0 million	'
Purchase order commitments	$41,000,000	'
Maximum period for purchase order commitments	'1 year	'
Number of milestones	6	'
Performance milestone payment term	'10 years	'
Aggregate milestone payments	320,000,000	'
Contingent consideration	$56,440,000	$67,000,000